Ironwood Financial llc Has $467,000 Stock Position in Bristol-Myers Squibb (NYSE:BMY)

Ironwood Financial llc reduced its position in Bristol-Myers Squibb (NYSE:BMY) by 6.2% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 9,029 shares of the biopharmaceutical company’s stock after selling 592 shares during the period. Ironwood Financial llc’s holdings in Bristol-Myers Squibb were worth $467,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. ESL Trust Services LLC bought a new position in Bristol-Myers Squibb during the first quarter valued at approximately $27,000. ORG Wealth Partners LLC bought a new position in Bristol-Myers Squibb during the third quarter valued at about $34,000. LGT Financial Advisors LLC boosted its stake in shares of Bristol-Myers Squibb by 42.7% during the 2nd quarter. LGT Financial Advisors LLC now owns 759 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 227 shares in the last quarter. Redmont Wealth Advisors LLC acquired a new position in shares of Bristol-Myers Squibb during the 1st quarter valued at about $47,000. Finally, MFA Wealth Advisors LLC bought a new position in shares of Bristol-Myers Squibb in the 2nd quarter valued at approximately $39,000. 76.41% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have commented on the company. StockNews.com raised shares of Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a research report on Monday, July 29th. Jefferies Financial Group lifted their target price on shares of Bristol-Myers Squibb from $49.00 to $51.00 and gave the stock a “hold” rating in a report on Wednesday, August 28th. Barclays upped their price target on shares of Bristol-Myers Squibb from $42.00 to $43.00 and gave the company an “underweight” rating in a report on Monday, October 7th. Deutsche Bank Aktiengesellschaft dropped their price objective on Bristol-Myers Squibb from $53.00 to $45.00 and set a “hold” rating on the stock in a research note on Tuesday, July 23rd. Finally, BMO Capital Markets reaffirmed a “market perform” rating and issued a $48.00 target price on shares of Bristol-Myers Squibb in a report on Monday, September 23rd. Two research analysts have rated the stock with a sell rating, fourteen have given a hold rating, one has given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $53.20.

Bristol-Myers Squibb Price Performance

NYSE BMY traded down $0.26 during trading on Thursday, reaching $53.11. 493,684 shares of the company traded hands, compared to its average volume of 14,752,871. Bristol-Myers Squibb has a 1-year low of $39.35 and a 1-year high of $57.59. The company has a market cap of $107.66 billion, a price-to-earnings ratio of -17.22, a P/E/G ratio of 13.75 and a beta of 0.46. The stock’s 50 day moving average price is $50.10 and its two-hundred day moving average price is $46.37. The company has a debt-to-equity ratio of 2.86, a quick ratio of 1.02 and a current ratio of 1.16.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Friday, July 26th. The biopharmaceutical company reported $2.07 earnings per share for the quarter, beating analysts’ consensus estimates of $1.64 by $0.43. The firm had revenue of $12.20 billion for the quarter, compared to analysts’ expectations of $11.54 billion. Bristol-Myers Squibb had a positive return on equity of 12.51% and a negative net margin of 14.06%. The business’s revenue was up 8.7% compared to the same quarter last year. During the same period in the prior year, the business posted $1.75 earnings per share. As a group, analysts anticipate that Bristol-Myers Squibb will post 0.77 EPS for the current year.

Bristol-Myers Squibb Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, November 1st. Shareholders of record on Friday, October 4th will be given a $0.60 dividend. The ex-dividend date is Friday, October 4th. This represents a $2.40 dividend on an annualized basis and a yield of 4.52%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently -77.42%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.